Navigation Links
Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End

ACTON, Mass., Feb. 23, 2012 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2011.  The Company also announced an increase in the quarterly dividend to $0.15 per share payable to shareholders of record as of March 5, 2012 to be paid on March 19, 2012.  This will be the Company’s 62nd consecutive quarterly dividend.

The Company's revenue for the year ended December 31, 2011 was $24.1 million, an increase of 20% as compared to $20.1 million for 2010.  Net income for the year ended December 31, 2011 was $3.5 million or $0.67 per share, an increase of 34% from 2010 during which the Company earned $2.6 million or $0.50 per share.  Revenue for the fourth quarter was $5.5 million, an increase of 8% as compared to $5.1 million in the fourth quarter of 2010.  Net income for the quarter was $438 thousand or $0.08 per share, an increase of 5% from $417 thousand or $0.08 per share for the same period of 2010.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "In 2011, sales and profits continued on the growth track.  While we are very proud that we have been profitable every year since 1993, including the severe 2009 recession, our focus continues to be sales and earnings growth.  The growth in 2011 can be attributed almost exclusively to the addition of new customers and introducing new programs to existing customers."  Kubacki continued: "Beyond the strong financial performance of 2011, the Company has made several investments in the future.  In December, the Company received its 7th patent, which focuses on liquefying hair and releasing drugs trapped in the hair without destroying the drugs.  The new patented method can be used with a broad range of immunoassay screen techniques, mass spectrometry methods, and chromatographic procedures.  This patent is fundamental to hair analysis drug testing because if you cannot get the drugs out of the hair, the drugs cannot be measured.  In addition, the Company received international accreditation (ISO/IEC 17025:2005) for a broad spectrum of laboratory testing including drugs of abuse and forensics in hair and urine specimens in the fourth quarter. The International Organization for Standardization/International Electrotechnical Commission (ISO/IEC) 17025 accreditation confirms international compliance and technical competence of the laboratory. This additional recognition affirms to our growing number of international clients, as well as domestic clients, that they are partnered with one of the highest quality laboratories anywhere in the world.  Finally, the Company has continued to invest in Sales and Marketing with additional staff and innovative programs."

Kubacki continued: "This year also marks the Company's 25 year anniversary milestone.  Since pioneering the use of hair testing for drugs of abuse over 25 years ago, Psychemedics has achieved global recognition as an innovative organization and technology leader in the field of drug testing. While the Company is proud to celebrate our history and significant achievements over the past 25 years, we look to the future for even greater success."

Kubacki concluded, "The Company's balance sheet remains strong with approximately $5.6 million in cash and cash equivalents and no long-term debt.  Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow.  Therefore, we are pleased to declare a 25% increase in our quarterly dividend to $0.15 per share. This dividend represents our sixty-second consecutive quarterly dividend.”

Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services.  Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.The Psychemedics web site is

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume sales, marketing strategies, and technological advantages) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.


Neil Lerner
Vice President Finance
(978) 206-8220
Neill@psychemedics.comPsychemedics CorporationStatements of Income Three Months EndedTwelve Months EndedDecember 31,December 31,(unaudited)(audited)2011201020112010Revenues

$5,546,942$5,116,237$24,089,608$20,108,862Cost of revenues

2,373,5112,034,1369,616,9858,067,229Gross profit

3,173,4313,082,10114,472,62312,041,633General & administrative

1,050,2801,435,8033,948,7064,195,998Marketing & selling

1,170,567851,5474,116,0592,949,739Research & development

207,623116,988607,408481,433Total operating expenses

2,428,4702,404,3388,672,1737,627,170Operating income

744,961677,7635,800,4504,414,463Interest income

5563,6695,34623,091Net income before provision for income taxes

745,517681,4325,805,7964,437,554Provision for income taxes

307,329264,4432,316,5131,823,834Net income

$438,188$416,989$3,489,283$2,613,720Basic net income per share

$0.08$0.08$0.67$0.50Diluted net income per share

$0.08$0.08$0.67$0.50Dividends declared per share

$0.12$0.12$0.48$0.48Weighted average common shares outstanding, basic

5,235,4225,212,4795,229,6465,207,244Weighted average common shares outstanding, diluted

5,240,1465,235,8005,235,9405,226,454Psychemedics CorporationBalance Sheets(audited)December 31,December 31,20112010ASSETS Current Assets:   Cash and cash equivalents

$5,564,233$3,720,488   Short-term investments

--2,018,452   Accounts receivable, net of allowance for doubtful accounts

4,490,9763,905,821of $169,191 in 2011 and $119,295 in 2010   Prepaid expenses and other current assets

565,508629,036   Income tax receivable

564,08371,786   Deferred tax assets  

315,501311,988Total Current Assets

11,500,30110,657,571Fixed Assets:   Equipment & leasehold improvements

13,089,65511,730,866   Less accumulated depreciation

(11,026,278)(10,663,996)Net Fixed Assets

2,063,3771,066,870   Other assets

237,174114,037Total Assets

$ 13,800,852$ 11,838,478LIABILITIES AND SHAREHOLDERS' EQUITYCurrent Liabilities:   Accounts payable

$961,844$699,833   Accrued expenses

1,321,8561,302,370   Deferred revenue

--16,605Total Current Liabilities

2,283,7002,018,808   Deferred tax liabilities, long term

482,52372,157Total Liabilities

2,766,2232,090,965Shareholders' Equity:   Preferred-stock, $0.005 par value, 872,521 shares authorized,

----no shares issued or outstanding   Common stock, $0.005 par value; 50,000,000 shares authorized

29,51829,3875,903,552 shares issued in 2011 and 5,877,358 shares issued in 2010   Paid-in capital

28,095,94627,764,992   Accumulated deficit

(7,009,046)(7,987,468)   Less - Treasury stock, at cost, 668,130 shares in 2011 and 665,345 shares in 2010

(10,081,789)(10,059,398)Total Shareholders' Equity

11,034,6299,747,513Total Liabilities and Shareholders' Equity


SOURCE Psychemedics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Psychemedics Awarded ISO/IEC 17025 International Accreditation
2. Pharmos Corporation Reports 2011 Fourth Quarter and Full Year Results
3. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
4. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
5. Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter
6. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
7. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
8. Unilife Corporation to Announce Financial Results for Fiscal 2012 Second Quarter on Thursday, February 9, 2012
9. Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex
10. Kensey Nash Corporation Announces Its Second Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
11. Terumo Americas Holding Acquires Onset Medical Corporation, a Leader in Innovative Sheath Technology Designed for Multiple, Minimally Invasive Clinical Applications
Post Your Comments:
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):